Sign up Australia
Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics bolsters expansion plans with new business advisory committee

Samuel Schwartz has been named as the BAC's inaugural chairman
doctor with patient
The firm's heart monitoring system allows clinicians to assess heart function

VentriPoint Diagnostics Ltd (CVE:VPT) has further bolstered its expansion plans, establishing a business advisory committee (BAC) and naming Samuel Schwartz as its inaugural chairman.

"We are very pleased to have Sam's many years of assisting small companies to grow internationally at our disposal," said Dr George Adams, chief executive at medtech firm Ventripoint.

"This is especially important at this time as the company looks at strategic approaches to growing its business."

"I am excited to have the opportunity to bring together a world-class group to advise Ventripoint on its goal to achieve better cardiac diagnosis and monitoring for everyone, especially children," said Dr Schwartz.

Schwartz was the managing partner of the Toronto office of DLA Piper Canada LLP, where he practised in many areas of the law, including corporate finance, structuring and securities law, and merchant banking.

His diverse clients included Canadian and foreign companies involved in the life sciences, biotech, computer hardware and software markets.

Last month, Ventripoint revealed it was among the top 50 performers on the TSX venture exchange over the last year, according to the exchange's ranking system.

The group has pioneered the VMSplus heart analysis device, and it (the company) has been added to the 2018 TSX Venture 50.

"2017 was a historical year for Ventripoint, our employees and shareholders, who have seen the company increase in market capitalisation by 384% and experience share price appreciation of 258%, while trading 206 million shares on the TSX Venture Exchange and 250mln shares on all share exchanges," said Dr Adams.

Its VMS Plus is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.

The company has developed a suite of applications for all major heart diseases and is actively commercialising the approach to improve cardiac care.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use